Back
Top 38%
17.9%
#1
11.9%
Top 0.4%
11.1%
Top 0.2%
6.5%
Top 45%
6.0%
Top 0.5%
6.0%
Top 2%
5.1%
Top 7%
5.1%
Top 27%
3.9%
Top 6%
2.0%
Top 21%
2.0%
Top 2%
1.2%
Top 11%
1.0%
Top 27%
1.0%
Top 0.5%
1.0%
Top 0.8%
0.7%
Top 3%
0.7%
Top 23%
0.7%
Top 24%
0.7%
Top 8%
0.7%
Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand
2022-03-12
pharmacology and therapeutics
Title + abstract only
View on medRxiv
Show abstract
We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (Cmin) above EC50 (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.
Predicted journal destinations
1
PLOS ONE
1737 training papers
2
Antimicrobial Agents and Chemotherapy
17 training papers
3
Clinical Pharmacology & Therapeutics
19 training papers
4
Frontiers in Pharmacology
27 training papers
5
Scientific Reports
701 training papers
6
British Journal of Clinical Pharmacology
21 training papers
7
Frontiers in Medicine
99 training papers
8
Clinical Infectious Diseases
219 training papers
9
Nature Communications
483 training papers
10
The Journal of Infectious Diseases
137 training papers
11
eLife
262 training papers
12
New England Journal of Medicine
49 training papers
13
Vaccines
131 training papers
14
BMC Medicine
155 training papers
15
Emerging Microbes & Infections
20 training papers
16
Journal of Antimicrobial Chemotherapy
19 training papers
17
Trials
24 training papers
18
PLOS Medicine
95 training papers
19
International Journal of Infectious Diseases
115 training papers
20
The Lancet Infectious Diseases
57 training papers